

Supplemental Material to:

Jingxuan Pan, Chun Chen, Yanli Jin, Enrique Fuentes-Mattei, Guermarie Velazquez-Torres, Juliana Maria Benito, Marina Konopleva, Michael Andreeff, Mong-Hong Lee and Sai-Ching Jim Yeung

Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells

2012; 11(12)

<http://dx.doi.org/10.4161/cc.20770>

<http://www.landesbioscience.com/journals/cc/article/20770>

Supplemental Figure Legends:


Supplemental Figure 1.

Similar to Figure 1A, the cell viability was measured by the MTS assay. The cell viability relative to the control samples was plotted against the concentration of human insulin (red), glargine (green) or aspart (blue). The data for Raji, CCRF-CEM and patients 2 to 7 are shown in panels as labeled.

Supplemental Figure 2.


- A) Similar to Figure 1B, the viability relative to control was measured for various metformin concentrations. Log-dose response curves are shown for ALL cell lines and primary patient samples not shown in Figure 1B (see color key).
- B) Similar to Figure 1C, the viability relative to control was measured for various rosiglitazone concentrations. Log-dose response curves are shown for ALL cell lines and primary patient samples not shown in Figure 1C (see color key).

Raji




Acute Lymphoblastic Leukemia Patient 2


CCRF-CEM




Acute Lymphoblastic Leukemia Patient 3




Acute Lymphoblastic Leukemia Patient 4





Acute Lymphoblastic Leukemia Patient 5




Acute Lymphoblastic Leukemia Patient 6



Acute Lymphoblastic Leukemia Patient 7



A**B**